Amlodipine (versus unexposed)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14425
R57260		 Mito, 2019 Preterm birth (<37 wks) at least 1st trimester retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 0.56 [0.26;1.24] C 10/48   41/129 51 48
ref
S13989
R54931		 Weber-Schoendorfer, 2008 Preterm children (<37 weeks) at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 4.19 [1.72;10.22] C 7/31   47/722 54 31
ref
Total 2 studies 1.52 [0.21;10.83] 105 79
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mito, 2019Mito, 2019 0.56[0.26; 1.24]514851%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Weber-Schoendorfer, 2008Weber-Schoendorfer, 2008 4.19[1.72; 10.22]543149%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 91% 1.52[0.21; 10.83]105790.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.52[0.21; 10.83]1057991%NAMito, 2019 Weber-Schoendorfer, 2008 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 4.19[1.72; 10.22]5431 -NAWeber-Schoendorfer, 2008 1 unexposed, sickunexposed, sick 0.56[0.26; 1.24]5148 -NAMito, 2019 1 Tags Adjustment   - No  - No 1.52[0.21; 10.83]1057991%NAMito, 2019 Weber-Schoendorfer, 2008 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 4.19[1.72; 10.22]5431 -NAWeber-Schoendorfer, 2008 1   - Only chronic hypertension indication  - Only chronic hypertension indication 0.56[0.26; 1.24]5148 -NAMito, 2019 1 All studiesAll studies 1.52[0.21; 10.83]1057991%NAMito, 2019 Weber-Schoendorfer, 2008 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 4.19[1.72; 10.22]5431 -NAWeber-Schoendorfer, 2008 1 unexposed, sick controlsunexposed, sick controls 0.56[0.26; 1.24]5148 -NAMito, 2019 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Bellos (Preterm birth (Randomized controlled ...Bellos (Preterm birth (Randomized controlled trial and Cohort studies)) 0.75[0.22; 2.51]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos (Preterm birth (Randomized controlled ...Bellos (Preterm birth (Randomized controlled trial only)) 1.50[0.19; 11.56]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.52[0.21; 10.83]91%79----Mito, 2019 Weber-Schoendorfer, 2008 20.510.01.0